DP4,a promising candidate for tumor immunotherapy
详细信息 查看官网全文
- 英文论文题名：DP4,a promising candidate for tumor immunotherapy
- 论文作者：Yin Kailin
- 英文论文作者：Yin Kailin ; Department of Immunology ; Peking University Health Science Center
- 年：2016
- 作者机构：Department of Immunology,Peking University Health Science Center;
- 英文论文关键词：DP4 ; transcriptional regulation ; tumor immunotherapy
- 会议召开时间：2016-11-04
- 会议录名称：第十一届全国免疫学学术大会摘要汇编
- 英文会议录名称：Abstracts of 2016 CSI Congress on Immunology
- 语种：英文
- 分类号：R730.51
- 学会代码：IGMD
- 会议名称：第十一届全国免疫学学术大会
- 会议地点：中国安徽合肥
- 主办单位：中国免疫学会
- 学会名称：中国免疫学会
- 页数：1
- 文件大小：1262k
- 原文格式：D
- 会议级别：全国
摘要
Previous studies have identified several cancer-testis antigens and a few among them have been applied to tumor immunotherapy in clinic. DP4, however, turns out to be a new member of the DP transcription-factor family and it is involved in dominating cell fate through modulating cell cycle arrest and apoptosis. After heterodimerization with E2F1, a nuclear protein playing a crucial role in cell proliferation and apoptosis, DP4 inhibits transcriptional activation of downstream genes. Four amino acids inside of the DNA-binding domain are responsible for its negative regulatory role on E2F1 activity. A C-terminal region outside of the DNA-binding domain might also be involved in this function. Utilizing DP4 epitopes to stimulate dendritic cells should evoke immune responses against DP4-positive tumor cells, making DP4 as a promising candidate for tumor immunotherapy. Here we point out the molecular structure and biological function of DP4, aiming to provide evidence of molecular mechanisms in regulating cell cycle and promoting survival. We demonstrate that DP4 is highly expressed in human malignancies and inhibiting DP4 would enhance cancer cell killing both in vivo and in vitro. These findings would have important implications in supporting the therapeutic value of DP4 in tumor immunotherapy.
Previous studies have identified several cancer-testis antigens and a few among them have been applied to tumor immunotherapy in clinic. DP4, however, turns out to be a new member of the DP transcription-factor family and it is involved in dominating cell fate through modulating cell cycle arrest and apoptosis. After heterodimerization with E2F1, a nuclear protein playing a crucial role in cell proliferation and apoptosis, DP4 inhibits transcriptional activation of downstream genes. Four amino acids inside of the DNA-binding domain are responsible for its negative regulatory role on E2F1 activity. A C-terminal region outside of the DNA-binding domain might also be involved in this function. Utilizing DP4 epitopes to stimulate dendritic cells should evoke immune responses against DP4-positive tumor cells, making DP4 as a promising candidate for tumor immunotherapy. Here we point out the molecular structure and biological function of DP4, aiming to provide evidence of molecular mechanisms in regulating cell cycle and promoting survival. We demonstrate that DP4 is highly expressed in human malignancies and inhibiting DP4 would enhance cancer cell killing both in vivo and in vitro. These findings would have important implications in supporting the therapeutic value of DP4 in tumor immunotherapy.
Previous studies have identified several cancer-testis antigens and a few among them have been applied to tumor immunotherapy in clinic. DP4, however, turns out to be a new member of the DP transcription-factor family and it is involved in dominating cell fate through modulating cell cycle arrest and apoptosis. After heterodimerization with E2F1, a nuclear protein playing a crucial role in cell proliferation and apoptosis, DP4 inhibits transcriptional activation of downstream genes. Four amino acids inside of the DNA-binding domain are responsible for its negative regulatory role on E2F1 activity. A C-terminal region outside of the DNA-binding domain might also be involved in this function. Utilizing DP4 epitopes to stimulate dendritic cells should evoke immune responses against DP4-positive tumor cells, making DP4 as a promising candidate for tumor immunotherapy. Here we point out the molecular structure and biological function of DP4, aiming to provide evidence of molecular mechanisms in regulating cell cycle and promoting survival. We demonstrate that DP4 is highly expressed in human malignancies and inhibiting DP4 would enhance cancer cell killing both in vivo and in vitro. These findings would have important implications in supporting the therapeutic value of DP4 in tumor immunotherapy.
引文